La epilepsia se refiere a un grupo de trastornos caracterizados por crisis recurrentes, que pueden ir acompañadas de convulsiones. El cannabis y las terapias a base de cannabis han demostrado tener efectos beneficiosos en varios tipos de epilepsia, a través de diferentes mecanismos biológicos.
Anticonvulsivo
Cerca del 60% de todas las crisis epilépticas son convulsivas, lo que significa que van acompañadas de convulsiones que se caracterizan por las contracciones rápidas, e involuntarias, de los músculos que pueden hacer que todo el cuerpo sufra temblores o sacudidas sin control. El tipo más común es la convulsión tónico-clónica, que consiste en un corto período de inmovilidad seguido de un temblor incontrolable. Ambos ataques epilépticos, los acompañados por convulsiones, y los que no, son causados por una actividad excesiva en las neuronas del cerebro. Si la actividad es grave y prolongada, las convulsiones pueden ocasionar daños en el tejido cerebral, sobre todo en los niños pequeños, cuando el cerebro todavía está en desarrollo. El síndrome de Dravet es sólo uno de los tipos de epilepsia que aparecen durante la infancia y que pueden causar daños neurológicos.
Hace siglos, si no milenios, que los seres humanos conocen las propiedades anticonvulsivas del cannabis. En 1947, los investigadores analizaron las propiedades anticonvulsivantes de los cannabinoides. En un primer estudio, realizado en la Universidad de Sydney en 1974, se demostró que Δ⁹-THC administrado en dosis elevadas tenía un efecto anticonvulsivo en ratones, a los que se les había hecho sufrir convulsiones administrándoles descargas eléctricas y químicas. Se observó que el CBD aumentaba este efecto del Δ⁹-THC, aunque los investigadores no pudieron comprobar que el CBD fuese eficaz por si mismo.
Desde entonces, varios estudios han demostrado que, de hecho, el CBD posee propiedades anticonvulsivas importantes por si solo, además de potenciar los efectos de Δ⁹-THC. Un estudio, elaborado en 2001, demostró que Δ⁹-THC y el análogo sintético de Δ⁹ THC, WIN 55.212-2, ejercen un efecto al agonizar los receptores CB₁. El CBD ejerce sus efectos de una forma diferente, ya que no agoniza el receptor CB₁ sino que actúa como un antagonista débil.
Aún no se ha establecido el mecanismo exacto utilizado por el CBD para controlar las convulsiones, pero está más que demostrado que resulta muy eficaz en el tratamiento de diversos tipos de epilepsia, entre los que se incluye el síndrome de Dravet en los niños pequeños, y ha ganado terreno, rápidamente, como posible tratamiento debido a su falta de psicoactividad, dejando en claro que es el efecto sinérgico y en conjunto de los cannabinoides los que hacen de esta planta una medicina.
Neuroprotector
A medida que avanza la investigación del sistema endocannabinoide, queda claro que éste desempeña un papel importante en la regulación de la duración y frecuencia de las convulsiones, de hecho, algunos investigadores creen que la epilepsia podría ocurrir como resultado de un desequilibrio inherente del sistema endocannabinoide (una supuesta enfermedad conocida como deficiencia endocannabinoide clínica), que podría surgir debido a una lesión cerebral, infección o predisposición genética.
La epilepsia puede afectar a diferentes zonas del cerebro, como al lóbulo temporal (© mitopencourseware)
En 2008, un estudio publicado en la revista Nature indicó que los pacientes que sufren epilepsia del lóbulo temporal parecían tener sistemas endocannabinoides disfuncionales. Como su propio nombre indica, la epilepsia del lóbulo temporal afecta al lóbulo temporal del cerebro, y por lo general produce crisis sin convulsiones que implican algún grado de perturbación sensorial (visual, auditiva, olfativa o gustativa incluso), aunque también puede producir convulsiones tónico-clónicas en los casos graves.
La causa común de las crisis convulsivas, y no convulsivas, es la excitación excesiva de las neuronas del cerebro, y la zona del cerebro que se ve afectada varía según el tipo de epilepsia. En pacientes sanos, se cree que los cannabinoides endógenos anandamida y 2-AG desempeñan un papel fundamental en la regulación del nivel de excitación neuronal, reduciendo así la probabilidad de que se desencadene un ataque. De este modo, en los pacientes que poseen un sistema endocannabinoide disfuncional, el cannabis y las terapias a base de cannabis pueden dirigirse, realmente, a la causa de la epilepsia y proporcionar un efecto neuroprotector que reduce la gravedad y la frecuencia de los síntomas.
El estado epiléptico
En casos muy graves de epilepsia, se puede producir una enfermedad conocida como status epilepticus o estado epiléptico. El estado epiléptico puede implicar crisis convulsivas, o no convulsivas, que o bien duran un período de más de cinco minutos cada una, o se producen con una frecuencia de más de un ataque cada cinco minutos sin recuperar la plena conciencia entre los mismos. Si al paciente no se le proporciona atención médica inmediata, durante un episodio de estado epiléptico, la pérdida prolongada de la función normal del cerebro puede ocasionar daño cerebral, o incluso la muerte. Si se proporciona una atención médica adecuada, los pacientes epilépticos suelen sobrevivir a un episodio de estado epiléptico sin mayores complicaciones.
El estado epiléptico suele tratarse con benzodiazepinas o barbitúricos. Ambas clases de fármacos son conocidos porque suelen producir una gran debilidad como efecto secundario, y están lejos de ser efectivos en general. Sin embargo, hay pruebas de que los cannabinoides, concretamente los agonistas de los receptores CB₁, como la anandamida, Δ⁹-THC, y el análogo sintético WIN 55.212-2, pueden proporcionar una mayor protección contra el estado epiléptico. En un estudio de 2006 publicado en el Journal of Pharmacology, WIN 55.212-2 demostró la capacidad de suprimir completamente todos los ataques, incluyendo los episodios prolongados asociados al estado epiléptico. El estudio también señaló que WIN 55.212-2 superaba con creces a la fenitoína y al fenobarbital a la hora de suprimir el estado epiléptico.
El fenobarbital suele utilizarse para tratar el estado epiléptico, aunque sin éxito total (Nottingham Vet School)
A partir de éste y otros estudios afines, realizados durante la última década aproximadamente, se ha demostrado que los agonistas de los receptores CB₁ son de fundamental importancia para suprimir las convulsiones, y prevenir la aparición de un estado epiléptico. Asimismo, se ha constatado que en los pacientes epilépticos, el que exista un desequilibrio en el sistema endocannabinoide aumenta la frecuencia y la gravedad de las convulsiones. En un artículo de 2007, se observó que si, a las neuronas epilépticas, se les administraba antagonistas de los receptores CB₁, se producía una actividad epiléptica continua, como la que se produce en los pacientes con estado epiléptico. Sin embargo, si se las trataba con agonistas de los receptores CB₁, la actividad excesiva se detenía. Por el contrario, cuando las neuronas no epilépticas recibieron tratamiento con antagonistas de los receptores CB₁, no se produjo ningún tipo de actividad excesiva parecida al estado epiléptico.
Por lo tanto, es evidente que tanto Δ⁹-THC como el CBD desempeñan un papel importante en el control de los ataques de la epilepsia. Sin embargo, aún no se entienden completamente los respectivos mecanismos de acción, en particular en el caso del CBD.
Bibliografia:
DESESPERADAMENTE BUSCANDO CBD, UN CAMINO EQUIVOCADO.
http://www.vice.com/read/desperately-seeking-cbd
El sentirse bien como pecado
Marijuana and Epilepsy (anecdotal- undated) http://www.rxmarihuana.com/epilepsy.htm
Treatment with CBD in oily solution of drug-resistant paediatric epilepsies.(abst – 2001) http://www.cannabismed.org/studies/ww_en_db_study_show.php?s_id=173&&search_pattern=EPILEPSY
Therapeutic Aspects of Cannabis and Cannabinoids (full – 2001)
http://bjp.rcpsych.org/cgi/reprint/178/2/107.pdf
Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in
mice. (abst – 2001) http://www.ncbi.nlm.nih.gov/pubmed/11442148
Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy.
(abst – 2001) http://www.ncbi.nlm.nih.gov/pubmed/11737161
The Endogenous Cannabinoid System Regulates Seizure Frequency and Duration in a
Model of Temporal Lobe Epilepsy (full – 2003)
http://jpet.aspetjournals.org/content/307/1/129.full?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=
cannabinoid&searchid=1&FIRSTINDEX=160&resourcetype=HWCIT
Experiences with THC-treatment in children and adolescents (abst – 2003)
http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=80
On the application of cannabis in paediatrics and epileptology. (abst – 2003)
http://www.ncbi.nlm.nih.gov/pubmed/15159680
Cannabis may help epileptics (news – 2003)
http://www.medicalnewstoday.com/articles/4423.php
Cannabis ‘could help epileptics’ (news – 2003) http://news.bbc.co.uk/2/hi/health/3162000.stm
Marijuana Use More Prevalent With Epilepsy (needs free registration)
(news – 2003) http://www.medscape.com/viewarticle/465891
Endocannabinoids and Their Implications for Epilepsy (full – 2004)
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1176361&tool=pmcentrez
Cannabinoids: Defending the Epileptic Brain (full – 2004)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1176332/?tool=pmcentrez
Marijuana use and epilepsy – Prevalence in patients of a tertiary care epilepsy center
(abst – 2004)
http://www.neurology.org/cgi/content/abstract/62/11/2095?maxtoshow=&hits=80&RESULTFORMAT=&f
ulltext=marihuana&searchid=1&FIRSTINDEX=1760&resourcetype=HWCIT
Epilepsy patients are smoking pot (news/ forum repost – 2004)
http://www.420magazine.com/forums/epilepsy/154906-epilepsy-patients-smoking-pot.html
Selective antiepileptic effects of N-palmitoylethanolamide, a putative endocannabinoid.
(abst – 2005) http://www.ncbi.nlm.nih.gov/pubmed/15461672
Fatty acid amidohydrolase in human neocortex-activity in epileptic and non-epileptic
brain tissue and inhibition by putative endocannabinoids. (abst – 2005)
http://www.ncbi.nlm.nih.gov/pubmed/15923084
Cannabinoids as potential anti-epileptic drugs. (abst – 2005)
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Retrieve&list_uids=16044663&dopt=abstrac
tplus
Not Too Excited? Thank Your Endocannabinoids (full – 2006)
http://www.sciencedirect.com/science/article/pii/S0896627306005927
Forebrain-Specific Inactivation of Gq/G11 Family G Proteins Results in Age-Dependent
Epilepsy and Impaired Endocannabinoid Formation (full – 2006)
http://mcb.asm.org/cgi/content/full/26/15/5888?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=can
nabinoid&searchid=1&FIRSTINDEX=1360&resourcetype=HWCIT
The Endocannabinoid System Controls Key Epileptogenic Circuits in the Hippocampus
(full – 2006) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1769341/?tool=pmcentrez
Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the
hippocampal neuronal culture model of acquired epilepsy (full – 2006)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808496/?tool=pmcentrez
Activation of the Cannabinoid Type-1 Receptor Mediates the Anticonvulsant Properties
of Cannabinoids in the Hippocampal Neuronal Culture Models of Acquired Epilepsy and
Status Epilepticus (full – 2006)
http://jpet.aspetjournals.org/content/317/3/1072.full?maxtoshow=&hits=80&RESULTFORMAT=&fulltext
=cannabinoid&searchid=1&FIRSTINDEX=320&resourcetype=HWCIT#ref-list-1
Cannabinoids In Medicine: A Review Of Their Therapeutic Potential (full – 2006)
http://www.doctordeluca.com/Library/WOD/WPS3-MedMj/CannabinoidsMedMetaAnalysis06.pdf
Arachidonyl-2′-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist,
enhances the anticonvulsant action of valproate in the mouse maximal electroshockinduced
seizure model. (abst – 2006) http://www.ncbi.nlm.nih.gov/pubmed/16930590
Brain’s Cannabinoid System ‘Mellows’ Seizures (news – 2006)
http://www.sciencedaily.com/releases/2006/08/060817103710.htm
Brain’s cannabinoid system fights seizures (news – 2006)
http://www.physorg.com/news75053658.html
Development of pharmacoresistance to benzodiazepines but not cannabinoids in the
hippocampal neuronal culture model of status epilepticus (full – 2007)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2094113/?tool=pmcentrez
Endocannabinoids block status epilepticus in cultured hippocampal neurons
(full – 2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2617750/?tool=pmcentrez
Downregulation of the CB1 Cannabinoid Receptor and Related Molecular Elements of
the Endocannabinoid System in Epileptic Human Hippocampus (full – 2007)
http://www.jneurosci.org/cgi/content/full/28/12/2976?maxtoshow=&hits=80&RESULTFORMAT=&fullte
xt=cannabinoid&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetyp
e=HWCIT
Marijuana: an effective antiepileptic treatment in partial epilepsy? (abst – 2007)
http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=157
Ultra-low dose cannabinoid antagonist AM251 enhances cannabinoid anticonvulsant
effects in the pentylenetetrazole-induced seizure in mice. (abst – 2007)
http://www.ncbi.nlm.nih.gov/pubmed/17870135
In Vitro Anticonvulsant Action of 2-Arachidonyl Glycerol (abst – 2007)
http://jkaumedsci.sa/kau/index.php/jkaumedsci/article/view/165
Rimonabant: safety issues (news – 2007)
http://www.xagena.it/news/medicinenews_net_news/09a11be6989d5a0e438dd9e589210a79.html
The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory
neurotransmission in the cerebellum. (full – 2008)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2438968/?tool=pubmed
The cannabinoid anticonvulsant effect on pentylenetetrazole-induced seizure is
potentiated by ultra-low dose naltrexone in mice (abst – 2008)
http://www.ncbi.nlm.nih.gov/pubmed/18502613
The effects of intracerebroventricular AM-251, a CB1-receptor antagonist, and ACEA, a
CB1-receptor agonist, on penicillin-induced epileptiform activity in rats.
(full – 2009) http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2009.02098.x/full
Prolonged exposure to WIN55,212-2 causes downregulation of the CB1 receptor and the
development of tolerance to its anticonvulsant effects in the hippocampal neuronal
culture model of acquired epilepsy. (full – 2009)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757117/?tool=pubmed
Effect of arachidonyl-2′-chloroethylamide, a selective cannabinoid CB1 receptor agonist,
on the protective action of the various antiepileptic drugs in the mouse maximal
electroshock-induced seizure model. (abst – 2009)
http://www.ncbi.nlm.nih.gov/pubmed/19751793
Involvement of nitrergic system in the anticonvulsant effect of the cannabinoid CB(1)
agonist ACEA in the pentylenetetrazole-induced seizure in mice. (abst – 2009)
http://www.ncbi.nlm.nih.gov/pubmed/19223154
Cannabinoid receptor activation reverses kainate-induced synchronized population burst
firing in rat hippocampus (abst – 2009)
http://www.frontiersin.org/integrative_neuroscience/10.3389/neuro.07.013.2009/abstract
Medical Marijuana and Epilepsy (news – 2009)
https://www.marijuanadoctors.com/content/ailments/view/79?ailment=epilepsy
Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo
(full – 2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2819831/?tool=pmcentrez
Cannabinoid-mediated inhibition of recurrent excitatory circuitry in the dentate gyrus in a
mouse model of temporal lobe epilepsy. (full – 2010)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871782/?tool=pubmed
AAV vector-mediated overexpression of CB1 cannabinoid receptor in pyramidal neurons
of the hippocampus protects against seizure-induced excitoxicity. (full – 2010)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3006205/?tool=pubmed
Delta-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure
activity in adult rats. (abst – 2010) http://www.ncbi.nlm.nih.gov/pubmed/20196794
Dynamic changes of CB1-receptor expression in hippocampi of epileptic mice and
humans. (abst – 2010) http://www.ncbi.nlm.nih.gov/pubmed/20618415
Endocannabinoid system protects against cryptogenic seizures. (full – 2011)
http://www.if-pan.krakow.pl/pjp/pdf/2011/1_165.pdf
Redistribution of CB1 Cannabinoid Receptors in the Acute and Chronic Phases of
Pilocarpine-Induced Epilepsy (full – 2011)
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0027196
Convulsions Associated with the Use of a Synthetic Cannabinoid Product.
(link to PDF– 2011)
http://www.springerlink.com/content/9651q2672027n38g/fulltext.html
Pro-epileptic effects of the cannabinoid receptor antagonist SR141716 in a model of
audiogenic epilepsy. (abst – 2011) http://www.ncbi.nlm.nih.gov/pubmed/21733658
Synthetic cannabinoid WIN 55,212-2 mesylate enhances the protective action of four
classical antiepileptic drugs against maximal electroshock-induced seizures in mice.
(abst – 2011)
http://www.unboundmedicine.com/medline/ebm/record/21238473/abstract/Synthetic_cannabinoid_WIN_5
5212_2_mesylate_enhances_the_protective_action_of_four_classical_antiepileptic_drugs_against_maxima
l_electroshock_induced_seizures_in_mice_
Protective effects of CB1 receptor agonist WIN 55.212-2 in seizure activity in the model
of temporal lobe epilepsy (abst – 2011)
http://www.unboundmedicine.com/medline/ebm/record/21469332/abstract/%5BProtective_effects_of_CB1
_receptor_agonist_WIN_55_212_2_in_seizure_activity_in_the_model_of_temporal_lobe_epilepsy%5D_
L-Type Calcium Channel Mediates Anticonvulsant Effect of Cannabinoids in Acute and
Chronic Murine Models of Seizure. (abst – 2011)
http://www.ncbi.nlm.nih.gov/pubmed/21928146
Changes in the cannabinoid (CB1) receptor expression level and G-protein activation in
kainic acid induced seizures. (abst – 2011) http://www.ncbi.nlm.nih.gov/pubmed/22079489
In vivo activation of endocannabinoid system in temporal lobe epilepsy with
hippocampal sclerosis. (abst – 2011) http://www.ncbi.nlm.nih.gov/pubmed/21303859
Marijuana, endocannabinoids, and epilepsy: Potential and challenges for improved
therapeutic intervention. (abst – 2011) http://www.ncbi.nlm.nih.gov/pubmed/22178327
Cannabis could help treat epilepsy (news – 2011)
http://www.newkerala.com/news/world/fullnews-186693.html
Cannabis could be used to treat epilepsy (news – 2011)
New research provides hope for those with epilepsy (news – 2011)
http://medicalxpress.com/news/2011-04-epilepsy.html
Neuron to Astrocyte Communication via Cannabinoid Receptors Is Necessary for
Sustained Epileptiform Activity in Rat Hippocampus (full – 2012)
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0037320
Cannabidivarin is anticonvulsant in mouse and rat. (full – 2012)
http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02207.x/pdf
Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy: Patent
Application 20120004251 (full – 2012)
http://www.freshpatents.com/-dt20120105ptan20120004251.php
Cannabinoid receptor 1 inhibition causes seizures during anesthesia induction in
experimental sepsis. (full – 2012)
http://journals.lww.com/anesthesiaanalgesia/
Fulltext/2012/06000/Cannabinoid_Receptor_1_Inhibition_Causes_Seizures.12.aspx
Acetaminophen inhibits status epilepticus in cultured hippocampal neurons.
(full – 2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3052417/
Inverse relationship of cannabimimetic (R+)WIN 55, 212 on behavior and seizure
threshold during the juvenile period. (abst – 2012)
http://www.ncbi.nlm.nih.gov/pubmed/22019959
Equipotent Inhibition of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase –
Dual Targets of the Endocannabinoid System to Protect against Seizure Pathology.
(abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22270809
Epileptiform activity in the CA1 region of the hippocampus becomes refractory to
attenuation by cannabinoids in part because of endogenous γ-aminobutyric acid type B
receptor activity. (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22388975
Cannabidiol for neurodegenerative disorders: important new clinical applications for this
phytocannabinoid? (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22625422
Statistical parametric mapping reveals regional alterations in cannabinoid CB1 receptor
distribution and G-protein activation in the 3D reconstructed epileptic rat brain.
(abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22509801
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial
seizures. (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22520455
Internet Highs-Seizures After Consumption of Synthetic Cannabinoids Purchased Online.
(abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22824736
Effect of ACEA-a selective cannabinoid CB1 receptor agonist on the protective action of
different antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model.
(abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22789660
First European case of convulsions related to analytically confirmed use of the synthetic
cannabinoid receptor agonist AM-2201. (abst – 2012)
http://www.ncbi.nlm.nih.gov/pubmed/22936123
Seizure exacerbation in two patients with focal epilepsy following marijuana cessation.
(abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/23159379
Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor
activation in a genetic model of absence epilepsy. (abst – 2012)
http://www.ncbi.nlm.nih.gov/pubmed/23206503
Inverse relationship of cannabimimetic (R+)WIN 55, 212 on behavior and seizure
threshold during the juvenile period (abst – 2012)
http://www.ncbi.nlm.nih.gov/pubmed/22019959
Science/UK: Antiepileptic efficacy of cannabidivarin will be tested in clinical studies
(news – 2012)
http://www.cannabis-med.org/english/bulletin/ww_en_db_cannabis_artikel.php?id=382
‘Hammer Head’ ‘incense’ blamed for seizure of youth in Le Roy (news – 2012)
http://thebatavian.com/howard-owens/hammer-head-incense-blamed-seizure-youth-le-roy/29983
How Medical Marijuana Is Giving a Six-Year-Old Boy New Life (news – 2012)
http://thinkprogress.org/justice/2012/09/18/854811/how-medical-marijuana-is-giving-a-six-year-old-boynew-
life/?mobile=nc
Alterations of endocannabinoids in cerebrospinal fluid of dogs with epileptic seizure
disorder. (full – 2013) http://www.biomedcentral.com/content/pdf/1746-6148-9-262.pdf
Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in
epilepsy-related gene expression. (full – 2013)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840466/
Medical Marijuana Coverage Still Lost in the Legal Weeds (article – 2013)
http://www.managedcaremag.com/linkout/2013/1/23
Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatmentresistant
epilepsy (abst – 2013)
http://www.sciencedirect.com/science/article/pii/S1525505013004629
Cannabis and other illicit drug use in epilepsy patients. (abst – 2013)
http://www.ncbi.nlm.nih.gov/pubmed/23311572
The Role of CB1-Receptors in the Proconvulsant Effect of Leptin on Penicillin-Induced
Epileptiform Activity in Rats. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23521910
The role of potassium BK channels in anticonvulsant effect of cannabidiol in
pentylenetetrazole and maximal electroshock models of seizure in mice. (abst – 2013)
http://www.ncbi.nlm.nih.gov/pubmed/23644464
Cannabinoid 1 receptor as therapeutic target in preventing chronic epilepsy
(abst – 2013)
http://www.fasebj.org/cgi/content/meeting_abstract/27/1_MeetingAbstracts/660.2?sid=eea722c0-971c-
4daa-8b8c-38c0c63c19ad
The du2J mouse model of ataxia and absence epilepsy has deficient cannabinoid CB1
receptor-mediated signalling. (abst – 2013)
http://www.ncbi.nlm.nih.gov/pubmed/23732642
The role of α2-adrenoceptors in the anti-convulsant effects of cannabinoids on
pentylenetetrazole-induced seizure threshold in mice. (abst – 2013)
http://www.ncbi.nlm.nih.gov/pubmed/23756131
CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence
epilepsy, reduce epileptic manifestations. (abst – 2013)
http://www.ncbi.nlm.nih.gov/pubmed/23860329
The secret «spice»: an undetectable toxic cause of seizure. (abst – 2013)
http://www.ncbi.nlm.nih.gov/pubmed/23983854
Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine,
oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures
in mice. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24161913
Therapeutic potential of cannabinoid medicines. (abst – 2013)
http://www.ncbi.nlm.nih.gov/pubmed/24006213
Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1
receptor-independent mechanism. (abst – 2013)
http://www.ncbi.nlm.nih.gov/pubmed/23902406
Epidiolex – GW Pharmaceuticals (drug development page – 2013)
http://www.gwpharm.com/Epidiolex.aspx
Science/Animal: CBD inhibits the activity of a certain liver enzyme (news – 2013)
http://www.cannabismed.
org/english/bulletin/ww_en_db_cannabis_artikel.php?id=391&search_pattern=2013#10
Cannabis Anti-Convulsant Shakes up Epilepsy Treatment (news – 2013)
New cannabis discovery could lead to better treatments for epilepsy (news – 2013)
http://www.reading.ac.uk/news-and-events/releases/PR464765.aspx
Parents of epileptic N.J. tot lament medical marijuana delays (news – 2013)
http://articles.philly.com/2013-06-24/news/40148313_1_marijuana-law-marijuana-card-dispensary
Medical Marijuana for Kids? Some Praise Results While Others Worry About Risks
(news – 2013) http://www.cnbc.com/id/100876423
New therapy for fragile X chromosome syndrome discovered (news – 2013)
http://www.sciencecodex.com/new_therapy_for_fragile_x_chromosome_syndrome_discovered-110170
Charlotte’s Web Of Suffering: Six-Year-Old Colorado Girl With Dravet Syndrome Finds
Relief From Marijuana High In CBD (news – 2013)
http://www.marijuana.com/news/2013/06/charlottes-web-of-suffering-six-year-old-colorado-girl-withdravet-
syndrome-finds-relief-from-marijuana-high-in-cbd/
Toronto family hopes for access to controversial treatment to cure baby’s rare epilepsy
(news – 2013)
http://globalnews.ca/news/714104/toronto-family-hopes-for-access-to-controversial-treatment-to-curebabys-
rare-epilepsy/
New Study: Cannabinoids Protect the Brain and Heart From Injury (news – 2013)
http://www.science20.com/news_articles/thc_can_prevent_brain_damage_study-113512
Families of children with epilepsy moving to Colorado, drawn by success of marijuana
oil (news – 2013)
http://gazette.com/families-of-children-with-epilepsy-moving-to-colorado-drawn-by-success-of-marijuanaoil/
article/1507895#AZpGzkjtp6Hzx785.99
Families migrate to Colorado for marijuana miracle (news – 2013)
http://www.denverpost.com/fitness/ci_24498723/families-migrate-colorado-marijuana-miracle?source=rss
Comes Now Epidiolex (FDA approves IND studies of CBD) (news – 2013)
http://www.beyondthc.com/comes-now-epidiolex-fda-approves-ind-studies-of-cbd/
Pharmaceuticals Provides Update on Orphan Program in Childhood Epilepsy for
Epidiolex® (news – 2013)
http://www.gwpharm.com/GW%20Pharmaceuticals%20Provides%20Update%20on%20Orphan%20Progra
m%20in%20Childhood%20Epilepsy%20for%20Epidiolex.aspx
Cannabis-Based Epilepsy Drug Approved For Clinical Trials (news – 2013)
http://www.medicaljane.com/2013/10/23/cannabis-based-epilepsy-drug-approved-for-clinical-trials/
OBTAINING EPIDIOLEX™ IN THE U.S. (news – 2013)
http://www.dravetfoundation.org/dravet-syndrome/consider-dravet/obtaining-epidiolex
Endogenous Signaling by Omega-3 Docosahexaenoic Acid-derived Mediators Sustains
Homeostatic Synaptic and Circuitry Integrity. (abst – 2014)
http://www.bioportfolio.com/resources/pmarticle/229933/Endogenous-Signaling-By-Omega-3-
Docosahexaenoic-Acid-derived-Mediators-Sustains-Homeostatic-Synaptic.html